Novo Nordisk Takes Legal Action Against Eli Lilly for Ad Claims

WHO:

NBC News - Novo Nordisk, a pharmaceutical company, and Eli Lilly, a competitor in the GLP-1 drug market.

CNBC - John Kuckelman, Novo's group general counsel.

WHAT:

[10:35 AM EDT] - CBS News - Novo Nordisk's lawsuit claims that Eli Lilly's ads create a "misleading impression" that its drugs are more effective, citing outdated studies.

[10:35 AM EDT] - CBS News - Novo Nordisk's high-dose Wegovy, which was recently approved, entered the market in March.

[10:35 AM EDT] - CBS News - A June Gallup study reported that 15% of U.S. adults have used GLP-1 medications for weight loss, up from 12% the previous year.

[10:35 AM EDT] - CBS News - Novo Nordisk alleges that Eli Lilly's advertisements are "maliciously and deceptively false" because they knowingly cite outdated clinical trials.

[10:35 AM EDT] - CBS News - The lawsuit claims that Eli Lilly's ads do not accurately reflect the existence of a higher dose of Wegovy, which is mentioned in "ambiguous" and "virtually invisible" footnotes.

NBC News - Novo Nordisk has filed a federal lawsuit against Eli Lilly for false advertising and unfair competition.

CNBC - The lawsuit alleges that Eli Lilly's advertising campaigns mislead consumers about the efficacy of its obesity and diabetes drugs compared to Novo's products.

CNBC - Novo Nordisk is seeking to permanently stop Eli Lilly from running the misleading ads and is requesting financial damages, though the amount is unspecified.

CNBC - Novo's high-dose version of Wegovy, which was recently approved, shows an average weight loss of around 19%.

WHERE:

CNBC - The lawsuit was filed in the U.S. District Court for the District of New Jersey.

WHEN:

CNBC - Novo Nordisk filed the lawsuit on a Tuesday.

CNBC - Novo Nordisk issued a formal cease-and-desist request to Eli Lilly in April.

WHY:

[10:35 AM EDT] - CBS News - Novo Nordisk argues that Eli Lilly's advertising misleads consumers by not including newer, more effective doses of its medicines that help achieve greater weight loss and blood sugar regulation.

NBC News - Novo Nordisk claims that Eli Lilly's ads rely on outdated clinical trials to create a misleading comparison of their drugs.

CNBC - The lawsuit is part of Novo's strategy to regain market share in the GLP-1 space against Eli Lilly's top-selling products.

HOW:

[10:35 AM EDT] - CBS News - Novo Nordisk plans to seek a preliminary injunction in the coming days to block Eli Lilly's ads immediately if they are not removed voluntarily.

CNBC - Novo Nordisk plans to seek a preliminary injunction to block the ads immediately if they are not removed voluntarily.

(UPDATED July 21, 2026 16:25 UTC)

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that the company's advertisements create a misleading impression about the effectiveness of its drugs, referencing outdated studies. The lawsuit comes shortly after Novo Nordisk's high-dose Wegovy, which was recently approved, hit the market in March. In response, Novo Nordisk plans to seek a preliminary injunction in the coming days to block Eli Lilly's ads if they are not removed voluntarily.

(UPDATED July 21, 2026 15:33 UTC)

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that the company's advertisements are "maliciously and deceptively false" for citing outdated clinical trials. The lawsuit argues that Eli Lilly's ads fail to accurately represent a higher dose of Wegovy, which is mentioned in what Novo Nordisk describes as "ambiguous" and "virtually invisible" footnotes, misleading consumers about the effectiveness of their medications. In response, Novo Nordisk plans to seek a preliminary injunction in the coming days to block Eli Lilly's ads if they are not removed voluntarily.

(UPDATED July 21, 2026 14:43 UTC)

Novo Nordisk has filed a federal lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, claiming false advertising and unfair competition. The lawsuit alleges that Eli Lilly's advertising misleads consumers about the effectiveness of its obesity and diabetes drugs compared to Novo's products, particularly highlighting Novo's recently approved high-dose version of Wegovy, which shows an average weight loss of around 19%. Novo is seeking to permanently stop Eli Lilly from running these misleading ads and plans to pursue a preliminary injunction if the ads are not removed voluntarily.